Company Overview
Company Type: Private Company
Website: www.phoenixmd.ca
Number of Employees: -
Year Founded: 2012
Total Amount Raised (CAD mm)†: 2.06
Total Rounds of Funding**:3
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Phoenix Molecular Designs Ltd develops small molecule kinase inhibitors as a targeted therapy for Cancer. The therapy can be used to cure breast cancer and Triple Negative Breast Cancer (TNBC). Phoenix Molecular Designs Ltd was founded in 2012 and is based in Vancouver, Canada with an additional office in San Diego, California.


Financial Information (Currency: CAD, in mm)
Total Revenue
-
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
-
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Dunn, Sandra 
Founder & CEO
Consaul, Morgan 
Marketing & Communications Manager

Key Board Members
Name
Title
Ashworth, Alan 
Member of Advisory Board
Olivo, Martin Sebastian
Member of Advisory Board
Varney, Michael D.
Member of Advisory Board


Primary Industry Classification
Biotechnology


Primary Office Location
220-887 Great Northern Way | Vancouver, BC | V5T 4T5 | Canada
Phone: 604-674-1796   

Current and Pending Investors
Investor
Initial Investment Date
Stake Type
Current Stake Amount
Round(s)
Adventure Capital Inc.
Feb-29-2020
Minority
-
Venture
Pallasite Ventures
Sep-18-2018
Unknown
-
Venture
The 51 Ventures
-
Unknown
-
-


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Feb-29-2020
Feb-29-2020
Private Placement
Target
Phoenix Molecular Designs Ltd
Adventure Capital Inc.

-
Nov-20-2019
Nov-20-2019
Private Placement
Target
Phoenix Molecular Designs Ltd
Pallasite Ventures

-
Sep-18-2018
Sep-18-2018
Private Placement
Target
Phoenix Molecular Designs Ltd
Pallasite Ventures

1.54
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Oct-27-2022
Executive/Board Changes - Other
Phoenix Molecular Designs Ltd Announces Appointment of Martin S. Olivo to Its Advisory Board
Feb-09-2022
Product-Related Announcements
Phoenix Molecular Designs Successfully Completes Patient Enrollment in Phase 1/1B Clinical Trial of Pmd-026
Mar-29-2021
Executive/Board Changes - Other
Phoenix Molecular Designs Appoints Michael Varney to Its Advisory Board
Feb-04-2021
Executive/Board Changes - Other
Phoenix Molecular Designs Announces Appointment of Alan Ashworth to its Advisory Board as a Scientific Advisor
Nov-24-2020
Product-Related Announcements
Phoenix Molecular Designs Announces First Patient Dosed in Phase 1b Clinical Trial of PMD-026 Taking Aim at Triple Negative Breast Cancer


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 14, 2023 09:17 PM
Phoenix Molecular Designs Ltd
Phoenix Molecular Designs
Reports
51
GlobalData

Jun 19, 2023 05:37 AM
Phoenix Molecular Designs Ltd
Phoenix Molecular Designs
Reports
51
GlobalData

Mar 16, 2023 04:59 AM
Phoenix Molecular Designs Ltd
Phoenix Molecular Designs
Reports
52
GlobalData

Mar 10, 2023 02:47 AM
Phoenix Molecular Designs Ltd
Phoenix Molecular Designs - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
28
GlobalData

Dec 14, 2022 05:36 PM
Phoenix Molecular Designs Ltd
Phoenix Molecular Designs
Reports
52
GlobalData

Dec 10, 2022 03:41 AM
Phoenix Molecular Designs Ltd
Phoenix Molecular Designs - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
28
GlobalData

Nov 15, 2022 04:49 AM
Phoenix Molecular Designs Ltd
Phoenix Molecular Designs - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
22
GlobalData

Sep 21, 2022 07:48 AM
Phoenix Molecular Designs Ltd
Phoenix Molecular Designs
Reports
52
GlobalData

Sep 15, 2022 03:53 AM
Phoenix Molecular Designs Ltd
Phoenix Molecular Designs - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
27
GlobalData

Jul 27, 2022 06:45 AM
Phoenix Molecular Designs Ltd
Phoenix Molecular Designs - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
21


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
PMD-026 (Future)

Key Board Members Details
Name
Title
Phone
Fax
Email
Ashworth, Alan 
Member of Advisory Board
(415) 476-5876
-

Olivo, Martin Sebastian
Member of Advisory Board
604-674-1796
-

Varney, Michael D.
Member of Advisory Board
604-674-1796
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Dunn, Sandra 
Founder & CEO
604-674-1796
-

Consaul, Morgan 
Marketing & Communications Manager
604 762-6443
-
mconsaul@phoenixmd.ca
* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
